ライフサイエンスコーパス: phenelzine

1 ne (DMI), or the monoamine oxidase inhibitor phenelzine.

2 ebo-treated patients originally treated with phenelzine.

3 s of anxiety would respond preferentially to phenelzine.

4 ents with symmetry obsessions did respond to phenelzine.

5 ulfate, pill placebo, and combined CBGT plus phenelzine.

6 , and the monoamine oxidase inhibitor (MAOI) phenelzine (10 mg/kg) increased BDNF protein levels in t

7 23% for patients maintained on a regimen of phenelzine, 41% for those maintained on a regimen of imi

8 ly greater after cognitive therapy (58%) and phenelzine (58%) than after pill placebo (28%).

9 s were randomly assigned to receive placebo, phenelzine (60 mg/day), or fluoxetine (80 mg/day).

10 of the gated-synchrony system in yeast with phenelzine, an antidepressant drug used in the treatment

11 Combined phenelzine and CBGT treatment is superior to either trea

12 Phenelzine and cognitive therapy also reduced symptoms s

13 rence rates after the switch to placebo from phenelzine and imipramine could be due to the two drugs'

14 We therefore hypothesized that phenelzine and imipramine would also affect brainstem GR

15 g effects of the monoamine oxidase inhibitor phenelzine and the tricyclic antidepressant imipramine o

16 report contrasting effects of chronic MAOI (phenelzine) and TCA (imipramine) treatment on neural cor

17 , 16 of 34 (47.1%) (CBGT), 19 of 35 (54.3%) (phenelzine), and 23 of 32 (71.9%) (combined treatment) (

18 n paroxetine, lithium augmentation more than phenelzine, and selegiline more than placebo.

19 otonin in rats treated with vehicle, DMI, or phenelzine but had no effect on the clearance of seroton

20 We show that phenelzine can block histone H3K4Me demethylation in cel

21 Imipramine typically increased and phenelzine decreased GR expression in other feedback-rel

22 The scores between cognitive therapy and phenelzine did not differ significantly.

23 addition, patients switched to placebo from phenelzine experienced a recurrence of depressive sympto

24 blood pressure rise in rats pretreated with phenelzine followed by tyramine, and in accord with the

25 nificantly more than those in the placebo or phenelzine group.

26 limited to feedback-related regions, whereas phenelzine had additional effects to decrease accumbens

27 f hepatotoxicity are iproniazid, nefazodone, phenelzine, imipramine, amitriptyline, duloxetine, bupro

28 y provides no evidence to support the use of phenelzine in OCD except possibly for those patients wit

29 GR expression was decreased by phenelzine in the locus coeruleus and decreased by imipr

30 Phenelzine increased locus coeruleus TH and imipramine i

31 noamine oxidase with daily administration of phenelzine increased nicotine intake by approximately 50

32 The neuroprotection observed with phenelzine is in agreement with previous studies of alde

33 depression are at high risk of recurrence if phenelzine is withdrawn 6 months after initial improveme

34 I-treated rats but not in those treated with phenelzine or DMI.

35 We re-explored MAO antidepressant agent phenelzine (phenethylhydrazine), previously reported to

36 monoamine oxidase inhibitors, we found that phenelzine provided robust neuroprotection in the gerbil

37 vival analysis showed a marked advantage for phenelzine relative to placebo.

38 eatment with the monoamine oxidase inhibitor phenelzine sulfate for social phobia.

39 e therapy or clinical management plus either phenelzine sulfate or placebo.

40 Cognitive behavioral group therapy (CBGT), phenelzine sulfate, pill placebo, and combined CBGT plus

41 hronic inhibition of monoamine oxidase using phenelzine sulfate.

42 After 12 weeks, phenelzine therapy and CBGT led to superior response rat

43 After 12 weeks, both phenelzine therapy and CBGT were associated with marked

44 therapy was more evident after 6 weeks, and phenelzine therapy was also superior to CBGT after 12 we

45 However, response to phenelzine therapy was more evident after 6 weeks, and p

46 Although phenelzine therapy was superior to CBGT on some measures

47 ents from 2 sites received 12 weeks of CBGT, phenelzine therapy, pill placebo administration, or educ

48 we investigated if the hydrazine function of phenelzine was capable of sequestering reactive aldehyde

49 e, we found that aldehyde sequestration with phenelzine was neuroprotective.

50 ed the discontinuation trial on a regimen of phenelzine were more chronically depressed than the imip

51 tion and who had improved with imipramine or phenelzine were stabilized for 6 months and then randoml